Abstract No: 8594 Background: Carfilzomib (CFZ) is a selective proteasome inhibitor approved in the US for the treatment of relapsed and refractory multiple myeloma (MM). This multicenter, single-arm phase 1/2 study (NCT01677858) is evaluating the safety and efficacy of once-weekly CFZ with dexamethasone (DEX). Methods: Patients (pts) with relapsed or refractory MM who received 1−3 […]
June 23, 2014
0 Comments